GlassScriptPhysician profile
Sheena P Buckelew
NPI 1588925069
$3,737.55
in general payments reported to CMS, 2019-2025
26 companies · $913 in 2025
The $913 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $759 · 2022: $570 · 2023: $419 · 2024: $1,077 · 2025: $913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,408.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,020.12 | 2021-2025 | |
| Lilly USA, LLC | $564.14 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $544.21 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $284.93 | 2021-2025 | Ozempic, Rybelsus, Esperoct |
| Otsuka America Pharmaceutical, INC. | $246.02 | 2021-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $175.23 | 2022-2025 | Xifaxan, Trulance |
| Pfizer INC. | $144.71 | 2023-2025 | |
| Glaxosmithkline, LLC. | $82.45 | 2021-2024 | Trelegy Ellipta |
| Biohaven Pharmaceuticals, INC. | $69.19 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $65.51 | 2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $63.05 | 2022 | |
| Axsome Therapeutics, INC. | $58.75 | 2024-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $54.12 | 2022 | |
| Lundbeck LLC | $51.39 | 2024-2025 | Rexulti |
| Genentech USA, INC. | $39.28 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $39.13 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $37.81 | 2025 | |
| Amgen INC. | $36.65 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $32.48 | 2024-2025 | Fanapt |
| Ibsa Pharma INC. | $29.72 | 2024 | Tirosint, Licart |
| Scynexis, INC. | $24.41 | 2022 | |
| Viatris Specialty LLC | $16.12 | 2025 | Yupelri |
| Sanofi Pasteur INC. | $15.91 | 2025 | |
| Alfasigma USA, INC. | $14.86 | 2022 | |
| Exact Sciences Corporation | $13.83 | 2025 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $13.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheena Buckelew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.